^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLAT overexpression

    i
    Other names: DLAT, Dihydrolipoamide S-Acetyltransferase, PDC-E2, DLTA, E2, Dihydrolipoyllysine-Residue Acetyltransferase Component Of Pyruvate Dehydrogenase Complex, Mitochondrial, Dihydrolipoamide Acetyltransferase Component Of Pyruvate Dehydrogenase Complex, 70 KDa Mitochondrial Autoantigen Of Primary Biliary Cirrhosis, E2 Component Of Pyruvate Dehydrogenase Complex, Pyruvate Dehydrogenase Complex Component E2, M2 Antigen Complex 70 KDa Subunit, PDCE2, PBC, Dihydrolipoyllysine-Residue Acetyltransferase
    Entrez ID:
    1737
    2years
    Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer. (PubMed, Sci Rep)
    There was a negative correlation between TIDE and DLAT expression (r = - 0.292, p < 0.001), which means high DLAT expression is an indicator of sensitivity to immunotherapy. In conclusion, our study constructed a four CRGs signature prognostic prediction model and identified DLAT as an independent prognostic factor and associated with resistant to HER2-targeted therapy for HER2-positive breast cancer patients.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • DLAT (Dihydrolipoamide S-Acetyltransferase)
    |
    HER-2 positive • DLAT overexpression
    |
    Herceptin (trastuzumab) • DA 3111 (trastuzumab biosimilar)
    2years
    Autoantibodies Against Dihydrolipoamide S-Acetyltransferase in Immune-Mediated Neuropathies. (PubMed, Neurol Neuroimmunol Neuroinflamm)
    Reactivity to DLAT was confirmed in patient sera, mainly in patients with CIDP. DLAT is highly expressed in the dorsal root ganglion cells, and anti-DLAT antibody may serve as a biomarker for sensory-dominant neuropathies.
    Journal
    |
    DLAT (Dihydrolipoamide S-Acetyltransferase)
    |
    DLAT overexpression
    over2years
    Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma. (PubMed, J Cancer Res Clin Oncol)
    Our findings identify a novel cuproptosis-related signature and the cuproptosis characteristics may influence the anti-tumor immunity though complex regulating networks, and thus cuproptosis may play a role in developing novel therapeutic target of ccRCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • DLAT (Dihydrolipoamide S-Acetyltransferase)
    |
    CTLA4 expression • DLAT overexpression